Dennison, E. M.-Fracture risk following intermission of osteoporosis therapy https://t.co/BGVJ5HFIJs
That #patients on #longtermtreatment (LTT) with #bisphosphonates, #denosumab should be offered a #drugholiday is not supported by #evidence. LTT with #antiresorptives is not associated with #risk of #fragility #fractures nd #skeletal #adversevents are rare
RT @Osteoporosis_NL: The view that patients on long-term treatment with bisphosphonates or denosumab should always be offered a drug holida…
The view that patients on long-term treatment with bisphosphonates or denosumab should always be offered a drug holiday is NOT supported by the existing evidence. Dennison, E et al. Osteoporos Int (2019). https://t.co/opo6hXgPiM ...nota bene!
RT @prieto_alhambra: New paper: systematic review on "Fracture risk following intermission of osteoporosis therapy" https://t.co/MthmcHHDyA
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
RT @prieto_alhambra: New paper: systematic review on "Fracture risk following intermission of osteoporosis therapy" https://t.co/MthmcHHDyA
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
RT @cpontesg: Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk…
Systematic review does not support drug holiday for tpatients on long-term treatment with bisphosphonates or denosumab: Risk after interruption may be explained by drug pharmacokinetics and patient risk factors, and long-term treatment is not associated w
RT @GtoSemi: Fracture risk following intermission of osteoporosis therapy “The view that patients on long-term treatment with bisphosphona…
RT @GtoSemi: Fracture risk following intermission of osteoporosis therapy “The view that patients on long-term treatment with bisphosphona…
RT @prieto_alhambra: New paper: systematic review on "Fracture risk following intermission of osteoporosis therapy" https://t.co/MthmcHHDyA
RT @prieto_alhambra: New paper: systematic review on "Fracture risk following intermission of osteoporosis therapy" https://t.co/MthmcHHDyA
New paper: systematic review on "Fracture risk following intermission of osteoporosis therapy" https://t.co/MthmcHHDyA
RT @GtoSemi: Fracture risk following intermission of osteoporosis therapy “The view that patients on long-term treatment with bisphosphona…
Fracture risk following intermission of osteoporosis therapy “The view that patients on long-term treatment with bisphosphonates or denosumab should always be offered a drug holiday is not supported by the existing evidence” https://t.co/WNKEg6m3yk
La prevención de la Osteoporosis, el tratamiento y su vigilancia, me interesa. Es una enfermedad silente y costosa para la sociedad. Vamos a educarnos.